Member Info for neilin62

OAPK20

Take a quick peek at a post i made 22 no NOV 21:23

Bit more on it.

Neil

Hi Techtonic

It's a shame that posts can't be edited, as it would be a lot easier for me to respond under each line of your post, so ill try and answer then in order as they appear.

lines 1, 2, and 3 The reference to Biotechne wasn't meant to infer that all these investors are buying in because of CIZ, it was meant to convey their confidence in Biotechne, as an expanding co. which is actively looking at mergers/takeovers, and given our involvement with them could be seen as a positive for us.

The subject of the dividend is in the same report, so i knew about that.

line 4. I hope you don't have reason to doubt my ability to demonstrate my discernment in my investment strategy.However i have always said no one should place any trust in their decision to invest, on my posting here. At the end of the day, you don't know me from Adam, and there are too many "investors" on these boards for the wrong reason. All i can promise, is that i am nor one of them. I do note that on recent posts, i have omitted to add the line about not relying on my information, so for that, i apologise.

line 5. Ties in a bit to line 4 and should not be relied upon. If anyone says they are 100% on all their investments, they are lying. NO-ONE is 100% - not even Warren Buffet will claim that. have i made some losses? yes, but in my terms not large ones. Have i made some good returns? yes. Have i made any spectacular returns? yes. 2. But that is all relative. What i detemine as "small" may be very large to some, so you can't really base success on that basis, as it is relative to each individual.

Line 6. Again, ties in with line 5. I do in general agree with your comment. Those admittedly, sometimes very plausible people, usually try to hammer home a figure. eg. 10p by Friday/ £1 by end of year etc. You will note that i have not, and will not ever specify a share price. I will not give anyone false hope/expectation.

re confirmation bias - As you should have deduced, i have a VERY substantial holding. Without wishing to sound condescending or up my own ar5e, can i afford to lose that amount of money? yes i can,. so the issue of having a heavier bias is not relevent.

Line 7.Since i am not religious in the slightest, my "unwavering " comment is based purely on my research.

Line 8. No i am not keeping a slightly open mind. My mind is COMPLETELY open. I want to know as much as i can about my investment, including any possible drawbacks, issues, concerns etc and if i find them i will find out everything i can. I have raised some concerns with the company, and had them responded to, and am happy with the response. Whenever needed, i have gone to independent sources to verify any concerns i may have had, and received responses to varying degrees depending on what they were able to divulge.

Hope this helps.

Remember though.....don't base your decisions on anything i post!!!!

Neil

Some big institutional investors know something?

Report released today shows who's increasing their stake in BioTechne.

Here are a few -

Investor increase in holdings % stake now held $

Select Equity Group 382.9% $592,919,000

Morgan Stanley 1, 300.4 % $247,200,000

William Blair Investment new holder $188,929,000

Norges Bank new holder $136,489,000

Mackenzie Financial Corp new holder $146,458,000

Institutions and hedge funds own 94.64% of the company's stock!

Neil

Hi Techtonic,

Sorry i am just responding, but not been home from work for long.

Yes i have been in communication recently.

My opinion is that a significant RNS will be lodged before long followed by an interview (Stockbox or Directors talk would be my guess) in which Allan will update us on what the RNS entails, and possibly news on further developments.

I'm not saying it is a definite, but i think on a significant RNS, there would be an opportune moment for a live Q&A session as we have had previously.

Last week Allan was "travelling" - see Greend100 post. - Wonder where he was travelling to /from?

re your last paragraph........ i have been in contact with with the company even before it became Cizzle Biotech, If you look back at my first ever posts, you will see my involvement. You may also find later posts in which i advised this bb about certain professionals i have been in communication with, and how i can guarantee that NHS are aware of us.

They will not tell me any more than they are allowed to, but i like to think that i have a bit of a handle on how to read what / how they are communicating. Hence my unwavering belief, and the reason for my VERY substantial investment.

PS, also not far from York

Neil

And in a further bit of news that could see Cizzle test being more urgently required by NHS.

If you have been following the saga of Illumina / Grail anti-trust case, it seems that Illumina have finally accepted defeat, and will unwind the merger ordered by the European Courts of Justice, & US Fifth Circuit Court of Appeals.

They announced Dec 17 2023, that Grail will be sold off by end of Q2 2024

Given that Illumina put up a significant investment in Galleri trial, it's not looking too good.

Neil

Although i hold investments in a number of companies, i really only post on this board as it is by far the best in my opinion. There are some really toxic childish exchanges on the majority of them, si i don't bother.

CIZ is a friendly, helpful and informative forum, by people that i believe are here for the right reasons. For me, it is just to try and help fellow investors to understand their investment, and hope you make some money.

It doesn't cost anything (okay sometimes a few quid for subscriptions to get information , and time etc) and i would really like to see it remain, so please can we try and keep it that way.

Okay, so as to why the perceived delay in any news, in my opinion, i don't see there is anything wrong. What i do believe, is that we are at a critical stage now, and that stage is where everything needs to amalgamate in order to release news.

By that, i mean that we were at research levels of Mabs, reagents etc, and needed to massively increase those levels to a commercial level. That takes time. Allan said that these will be the ones used for commercial launch in conjunction with BioTechne JESS platform, and need to be validated in terms of storage, shelf life, stability, batch and quality control etc and how they are distributed. We are not just putting this test into the local Boots pharmacy, we need to ensure they will survive being distributed across the world.

In tandem with this, is the work going on to receive reimbursement codes so that we can sell the test, and receive payment.

We can't do a product launch without all these processes coming together. Imagine a couple of scenarios..... we launch the test, but then find we don't have enough compounds - disaster.!, Or we get enough compounds and launch in USA, then find we haven't been granted reimbursement codes, so we can't apply for payment - disaster!

I for one (as frustrating as the wait is) want them to get everything right, and get this into market with no issues.

Just as a note on the discussions on sensitivity, even IF (it won't be) sensitivity is 75% as has been mentioned, it will not be seen as poor, because at the very least, it will still be far better than anything out there.

THere is also the possibility that it may be slightly better than the 95% mentioned. The reason i say this, is because during the process of manual transfer from pipette to the Jess cell, is where errors are made.

In our case, our platform is fully automated, and will reduce the incidence of errors.

I don't think it will be long before we get news, and an interview with Allan, and a further news flow thereafter.

Neil

No, nothing gone wrong.

Just bought another 300,000 but couldn't get them in one go.

Neil

From London Stock Exchange

Thursday trade volume 1,430,228

Friday trade volume 424,808

Neil

OAPK20,

No, the CAP accreditation is held by the laboratory developing the test.

Techtonic,

All questions are highly relevant, and good that people ask them rather than not questioning, but for the reasons i posted, i don't believe that we will have much, if anything to worry about.

As Brondy also touched on, we have Dawn Coverley with 20 years of extensive research on this, and with Corepath and Biotechne behind us, with their contacts, expertise, partners in US, and previous experience, that just adds more credence to us.

The whole issue with the lobbyists is to protect their interest. The issue with FDA is the evidence in what is being claimed in test results. Our test results, validation, etc will, i believe stand up to any scrutiny.

OBD's issues are not the same, although in my opinion, because of the disaster of an RNS and it's claims on slaes (that appear to have been misleading) this is a convenient thing to try and pass the blame onto.

Neil

Morning VincentVega

This has been raised over and over by certain groups lobbying the FDA and they are still no further forward.

As Brondby says it will be years if we see any effect.

One thing in our favour is the fact that Corepath are CLIA , and CAP accredited.

The other thing is that our test will be listed in the class 11b device under IVD list B product, so deemed low to medium risk, and not subject to the more stringent requirements of other class devices.

Even IF the lobbyists do get an ammendment, it will likely be 4 years minimum from the date of final publication (add probably another year for that) and FDA reckon it will take 3 years to get staff in place to oversee the regulations, so i personally don't see it affecting us.

On another note, a comment by someone the other day mentioned Bill Behnke being on the payroll. Just to clarify he isn't on the payroll, but we have an agreement where he and the Behnke group are responsible for the marketing of our products in USA.

In a great bit of business sense, Cizzle entered into an agreement where Behnke group will be paid ON RESULTS. Love that for an incentive.

Incidentally it was Bill that introduced us to Corepath, and with who Behnke group have many customers.

Lovelyboy, if you are looking in, have a look at OBD webinar that VV posted today......and you wasn't sure if i was pulling your leg when i mentioned about the size of the vetinary market :-)

Neil

Evening OAPK20

Effectively, that is exactly what we have.

Once we have clearance in USA, a route to China market.

The agreement with China is 10% royalty on our kit, in addition to the supply of the reagents / antibodies, and any other use of the technology.

It makes perfect sense to utilise Jess, since that IS the platform on which our test is validated. In my mind, there must be some agreement following, whereby Cizzle says to Biotechne " we are promoting your hardware, so will licence our proven technology to you to offer a turnkey package. All proven, and cleared/approved"

But then that makes it a worldwide market, since Biotechne will be keen to say to their customers throughout the WORLD "here you go - a ready made package with unrivalled accuracy / sensitivity, with their machine being the key.

That in itself is a hell of a potential, but when you then factor in that we have developed a library of biomarkers to detect other cancers, and we already know that breast cancer test kit is being developed now, it starts to get really interesting for both us and Biotechne.

If that wasn't enough..... remember the line "accelerate our development of a lateral flow test"

So many facets to the potential here, it is hard to get your head around it.

Neil

Neil

Also, don't forget about NHS !

Once we have clearance in USA, we are virtually straight into NHS territory.

We are already in the stage "supporting of market launch in NHS"

Neil

Vincent Vega

The whole premise of this test is that it utilises CIZ1B

The quickest route to market is via LDT in a CLIA accredited facility (Corepath)

The China test cannot take place without Cizzle supplying the reagents & monoclonal antibodies. Therefore running 2 sets of test simultaneously can't take place.

ICCAMT are contracted to develop the test and bring it to market, and to that end, i think that the test will be launched in USA, and because China will be using the platform, i think it is fairly certain that Jess will be that platform, because it doesn't make sense to start all over again with a new platform. After all, the longest part of getting it to market is validating the the technology, and this can be done by using data gathered in the USA test. So once in the market in USA, i expect the time required to get into China market significantly reduced.

Biotechne already in China, so will be able to supply the hardware. Don't forget that the agreement already includes for Cizzle to be paid for the supply of the antibodies and reagents, in addition to any other services provided using CIZ1B.

Neil

Hi Fastfood

I don't like putting timescales on it for obvious reasons, and if i miss it by a few days/weeks it doesn't suit someones timescale.

However, if you are reading / thinking the same as me.....

before end of March, either 2-3 RNS's or one HUGE one ;-))

Neil

You know i don't give a flying fig for the day to day share price, but watch and see what happens in the next few days.

£30k worth of trades does not impact the MC to the extent of 9.2% drop. (Approx £800k)

My bet is the price has been dropped to facilitate collection of shares cheaply.

Neil

Hi Bearsandbulls,

I said previously when commenting about Grails claims on Galleri, that it is important to look past the attention grabbing headlines.

At first glance, you would be forgiven for thinking (that some on here may have) that they are virtually about to launch their test kit into the market.

When you look at the actual content of the report, it makes it clear that this was only a study, and is in the very early stages. In fact one paragraph, states "could be a starting point for developing a new generation of screening tests for the early detection of cancer"

Their study reports sensitivity of 80%, but across stage I & II cancer. Ours is 95%

Yes, you could well be right in thnking that they are sounding out the market for potential funding.

Neil

Interesting that they decided to release this "news" in the last day or two, considering it was previously released 8th May 2023.

One of the things to watch out for is the claims that they can detect multiple cancers.

The problem there is that many blood tests to detect tumour markers are available or under development, but many are hampered

by the fact that tumour markers may also be produced by normal cells in the body. In contrast, the Cizzle

Biotechnology test is based on tumour-specific technology. A number of the tests specific to lung cancer

look at particular alterations of circulating DNA (cDNA) and RNA (cRNA), and are used to determine the

precise type of cancer, define which therapy is more likely to work and assess the effectiveness of a particular

drug. Few tests are aimed at early detection and reducing significantly the number of false positives achieved

via CXT and chest CT scans.

(Clinical biomarkers have been instrumental in reducing mortality in cancer patients [29], however lack of understanding of the capability of biomarker tests can result in inappropriate use and lead to over-investigation of disease that is incorrectly assumed to be malignant [30]. Furthermore the value of some has been questioned especially in relation to their use in the initial diagnosis of cancer [29], [31]. Lack of clarity usually arises when a marker is found in other pathologies or when, like PSA, it is not specific for neoplastic cells.)

Neil

Correction,

The £1m was issue of 25m shares

47m was the TOTAL number of shares

Neil

The deal was structured by:

£1m by way of issue of 47m shares at a price of 4p per share, when the share price on the previous closing day was 2.53p - a premium of 56.9%

£880,000 by way of issue of 22m shares at a price of 4p per share, when the share price on the previous closing day was 1.65p - a premium of 135%

If shares had been issued at their true value, then we would have had to issue in excess of 92m shares.

The CDT put option premium was settled by way of issue of 7,371,557 shares at 1.6p per share.

Total cost was £2.2m factoring in everything, so anything above that is a good investment. Especially if you factor in the true cost had it not been for the shares premiums paid by the investors.

As Brondby says, we don't know the true value yet. It may be considerably more in time. Until the BOD tell us their intentions, (sell some and hold the rest for future, , sell all, hold all) we just don't know. But it does give us options and is pretty much guaranteed funding for future.

Neil

Apologies, but it's another long one...

So iv'e been looking back over my notes, interviews, etc, and this is what i found -

We know Allan was in China at the end of September, at the invitation of the Department of Business and Trade,.

Rahul Agarawal is the UK diplomat, and arranged by PhRIDA (Pharmaceutical Innovation and Research Development Association) where a "mini mission" of 11 Uk companies were present.

Allan presented "PROJECT 3 " Cizzle Biotechnology to the audience at 3pm on the 25th Sept followed by one to one meetings and investment dinner with key China healthcare organisations.

He has stated that he will report back what is happening on these meetings.

I also made note of a few statements from previous interviews. Among them were:

Whilst speaking about acceleration of lateral flow kit development -

"Dr Coverley will be knocking on the door of the next product"

"We are going to be doing that at the same time"

"That will be for another interview"

"A lot more to tell you about, at the right time"

"Chapter 2 coming up"

It seems there is a lot of news in the pipeline.

In the last prospectus for the E3 funding, -

"the company will also seek LICENSING AND JOINT VENTURE FEES" I said previously about the alternative revenue from licensing deals. Now joint ventures too.

Now here's an interesting observation from Bio-techne business development -

"......our teams focus is on building business development and technology in-licensing opportunities with owners of existing innovations or intellectual property, that are seeking to further develop products, or introduce their technology to larger markets".

Just a mention too of the original investors when CIZ did the IPO.

Their warrants are due to be exercised by 14th May 2024, at a strike price of 15p.

Neil